

Product datasheet for AM00801PU-N

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Apolipoprotein A I (APOA1) Mouse Monoclonal Antibody [Clone ID: 057-16001]

Product data:

Product Type: Primary Antibodies

Clone Name: 057-16001
Applications: ELISA, R
Reactivity: Human
Host: Mouse
Isotype: IgG2a

Clonality: Monoclonal

Immunogen: Human High Density Lipoprotein.

Specificity: This antibody recognizes Apolipoprotein A I.

This product does not cross react with Apo All or Apo B in competitive RIA.

Formulation: 10mM Phosphate, pH 7.4 containing 150mM Sodium Chloride and 0.09% Sodium Azide

State: Purified

State: Liquid (0.2µm filtered) purified IgG fraction (>90% pure by SDS-PAGE).

Concentration: lot specific

Purification: Protein A Chromatography.

Conjugation: Unconjugated

Storage: Store the antibody undiluted at 2-8°C for one week or (in aliquots) at -20°C for longer.

If aliquoted for long term storage, fill volume should be equal to or greater than 50% of the

nominal fill volume of the vial used. Avoid repeated freezing and thawing.

Stability: Shelf life: one year from despatch.

Gene Name: apolipoprotein A1

Database Link: Entrez Gene 335 Human

P02647





Background:

Apolipoprotein A I promotes cholesterol efflux from tissues to the liver for excretion. Apolipoprotein A I is the major protein component of high density lipoprotein (HDL) in the plasma. Synthesized in the liver and small intestine, it consists of two identical chains of 77 amino acids; an 18 amino acid signal peptide is removed co-translationally and a 6 amino acid propeptide is cleaved post-translationally. Apolipoprotein A I is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. Defects in the Apolipoprotein A I gene are associated with HDL deficiency and Tangier disease.

The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I. The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases.

Synonyms: APOA1, ApoA-I, Apo-AI, ApoAI

Note: Centrifuge before opening to ensure complete recovery of vial contents.